Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dapagliflozin + linagliptin + metformin (Dios Lifesciences)
- Development stage
- Phase 3
- Lead developer
- AJU Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Dapagliflozin + linagliptin + metformin** is a fixed-dose oral combination of three antidiabetic drugs used in the management of type 2 diabetes mellitus when monotherapy or dual therapy is insufficient. - **Dapagliflozin**: A sodium-glucose co-transporter 2 (**SGLT2**) inhibitor that lowers blood glucose by increasing urinary glucose excretion. - **Linagliptin**: A dipeptidyl peptidase-4 (**DPP-4**) inhibitor that increases incretin levels, leading to increased insulin secretion and decreased glucagon release. - **Metformin**: A biguanide that decreases hepatic glucose production, reduces gastrointestinal absorption of glucose, and enhances insulin sensitivity. The combination enables complementary glucose-lowering mechanisms, improved glycemic control, and may reduce the risk of diabetes-related complications. It is used as an adjunct to diet and exercise in adults with type 2 diabetes.
- Brand names
- Linaget DMOndero-DMLinaliglip DapametJuslina DMLinaxa DMLinero-DMDapaglyn LMLinapil DMLinapride DMLaglin 5DMLaglin5DMLaglin-5DM
- Other names
- dapagliflozin + linagliptin + metformin hydrochloridedapagliflozin/linagliptin/metformindapagliflozin-linagliptin-metformin
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)ND1 (Mitochondrial electron transport chain complex I)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on dapagliflozin + linagliptin + metformin (Dios Lifesciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dapagliflozin + linagliptin + metformin (Dios Lifesciences).